Revenues de-grew 1.8% YoY to | 1420 crore (I-direct estimate: | 1547 crore). Revenues in the pharmaceutical business (including drug discovery segment) grew 10.1% YoY to | 802 crore while life science ingredients (LSI) revenues de-grew 13.9% YoY to | 618. Degrowth in the LSI segment was mainly due to lower crude prices and optical focus on profitable products. EBITDA margins increased ~345 bps YoY to 25.9% (I-direct estimate: 21.8%) on the back of 180 bps increase in both pharmaceutical and LSI margins to 34% and 19%, respectively.Adjusted net profit grew 22.8% to | 162 crore (I-direct estimate:| 132 crore) due to better operational performance and lower interest cost.